Skip to content
10-K

Annual Report

OptimizeRx Corp OPRX

0001213900-25-025576

← back to feed
Filed
Mar 20, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2024 · Mar 11, 2025 18.49M sh
Shares Diluted FY 2024 · Dec 31, 2023 17.12M sh
Stock Repurchased restated FY 2024 · Dec 31, 2023 $7.52M
Capex restated FY 2024 · Dec 31, 2023 $87K
Operating Cash Flow restated FY 2024 · Dec 31, 2023 −$7.24M
Long Term Debt restated FY 2024 · Dec 31, 2023 $34.23M
Short Term Debt FY 2024 · Dec 31, 2023 $2M
Cash And Equivalents restated FY 2024 · Dec 31, 2023 $13.85M
Current Liabilities restated FY 2024 · Dec 31, 2023 $17.88M
Total Liabilities restated FY 2024 · Dec 31, 2023 $56.82M
Current Assets restated FY 2024 · Dec 31, 2023 $54.33M
Total Assets restated FY 2024 · Dec 31, 2023 $183.37M
Eps Diluted FY 2024 · Dec 31, 2023 −$1.03
Eps Basic FY 2024 · Dec 31, 2023 −$1.03
Net Income restated FY 2024 · Dec 31, 2023 −$17.57M
Operating Income restated FY 2024 · Dec 31, 2023 −$26.4M
Gross Profit restated FY 2024 · Dec 31, 2023 $42.9M
Cost Of Revenue restated FY 2024 · Dec 31, 2023 $28.62M
Stockholders Equity restated FY 2024 · Dec 31, 2022 $126.11M